Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Milademetan - Daiichi Sankyo

Drug Profile

Milademetan - Daiichi Sankyo

Alternative Names: DS-3032; DS3032b; RAIN-32

Latest Information Update: 11 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rigel Pharmaceuticals
  • Developer Daiichi Sankyo Inc; National Cancer Center Hospital East; Rain Oncology; University of Texas M. D. Anderson Cancer Center
  • Class Amides; Antineoplastics; Cyclohexanes; Halogenated hydrocarbons; Indoles; Pyrans; Pyrrolidines; Small molecules; Spiro compounds
  • Mechanism of Action Proto-oncogene protein c mdm2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liposarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Liposarcoma
  • Phase II Sarcoma; Solid tumours
  • Phase I/II Acute myeloid leukaemia
  • Phase I Unspecified
  • Preclinical Malignant-mesothelioma
  • No development reported Lymphoma; Multiple myeloma; Myelodysplastic syndromes

Most Recent Events

  • 21 Dec 2023 Rain Oncology in collaboration with Institut Curie terminates the phase II DEMETER trial for HER2-negative Breast cancer (Late-stage disease, Metastatic disease, Combination therapy, Second-line therapy or greater) in France (NCT05932667)
  • 20 Oct 2023 Updated efficacy and adverse events data from a phase III MANTRA trial in Liposarcoma presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
  • 15 Oct 2023 Rain Oncology terminates a phase II MANTRA-2 trial for Solid tumours (Late-stage disease, Second-line therapy or greater, In adults, In the elderly, Metastatic disease) in USA (PO) due to sponsor's decision (NCT05012397)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top